MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway

Carcinogenesis

Volumn 33, Issue 5, 2012, Pages 976-985

  Lynch, Jennifer ^a,b   Fay, Joanna ^a,b   Meehan, Maria ^a,b   Bryan, Kenneth ^a,b   Watters, Karen M ^a,b   Murphy, Derek M ^a,b   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

LRG1 PROTEIN; MICRORNA; MICRORNA 335; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN; RHO KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MYCN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVITY; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE;

EID: 84860473453     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs114     Document Type: Article

References (57)

1. Brodeur, G.M. (2003) Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer, 3, 203-216.
2. Almeida, M.I. et al. (2010) MicroRNAs and metastases-the neuroblastoma link. Cancer Biol. Ther., 9, 453-454.
3. Matthay, K.K. et al. (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol., 27, 1007-1013.
4. Stallings, R.L. (2007) Are chromosomal imbalances important in cancer? Trends Genet., 23, 278-283.
5. Brodeur, G.M. et al. (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 224, 1121-1124.
6. Murphy, D.M. et al. (2009) Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One, 4, e8154.
7. Murphy, D.M. et al. (2011) Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol. Carcinog, 50, 403-411.
8. Murphy, D.M. et al. (2011) Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma. PLoS One, 6, e21436.
9. Westermann, F. et al. (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol., 9, R150.
10. Inman, G.J. (2011) Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr. Opin. Genet. Dev., 21, 93-99.
11. Meulmeester, E. et al. (2011) The dynamic roles of TGF-beta in cancer. J. Pathol., 223, 205-218.
12. Zhang, Y.E. (2009) Non-Smad pathways in TGF-beta signaling. Cell Res., 19, 128-139.
13. Scarpa, S. et al. (1996) Transforming growth factor beta regulates differentiation and proliferation of human neuroblastoma. Exp. Cell Res., 229, 147-154.
14. Turco, A. et al. (2000) Increased TGFbeta type II receptor expression suppresses the malignant phenotype and induces differentiation of human neuroblastoma cells. Exp. Cell Res., 255, 77-85.
15. Kim, V.N. (2005) Small RNAs: classification, biogenesis, and function. Mol. Cells, 19, 1-15.
16. Stallings, R.L. (2009) MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr. Pharm. Des., 15, 456-462.
17. Stallings, R.L. et al. (2010) Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin. Ther. Targets, 14, 951-962.
18. Foley, N.H. et al. (2010) MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol. Cancer, 9, 83.
19. Tivnan, A. et al. (2010) MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res., 30, 4391-4395.
20. Tivnan, A. et al. (2011) MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer, 11, 33.
21. Cole, K.A. et al. (2008) A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res., 6, 735-742.
22. Wei, J.S. et al. (2008) The MYCN oncogene is a direct target of miR-34a. Oncogene, 27, 5204-5213.
23. Welch, C. et al. (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, 26, 5017-5022.
24. Bray, I. et al. (2011) MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett., 303, 56-64.
25. Foley, N.H. et al. (2011) MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ., 18, 1089-1098.
26. Fontana, L. et al. (2008) Antagomir-17-5p abolishes the growth of therapyresistant neuroblastoma through p21 and BIM. PLoS One, 3, e2236.
27. Mestdagh, P. et al. (2010) The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol. Cell, 40, 762-773.
28. Xu, Y. et al. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene, doi: 10.1038/onc.2011.340.
29. Bray, I. et al. (2009) Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One, 4, e7850.
30. Mestdagh, P. et al. (2010) MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYCactivated tumors. Oncogene, 29, 1394-1404.
31. Schulte, J.H. et al. (2010) Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int. J. Cancer, 127, 2374-2385.
32. Itoh, K. et al. (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med., 5, 221-225.
33. Irizarry, R.A. et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res., 31, e15.
34. Bolstad, B.M. et al. (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics, 19, 185-193.
35. Li, X. et al. (2007) Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus. Neurosci. Lett., 413, 141-144.
36. Huang, C. et al. (2004) MAP kinases and cell migration. J. Cell Sci., 117, 4619-4628.
37. Vicente-Manzanares, M. et al. (2009) Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat. Rev. Mol. Cell Biol., 10, 778-790.
38. Duxbury, M.S. et al. (2004) Inhibition of pancreatic adenocarcinoma cellular invasiveness by blebbistatin: a novel myosin II inhibitor. Biochem. Biophys. Res. Commun., 313, 992-997.
39. Pearson, G.W. et al. (2007) Real-time imaging reveals that noninvasive mammary epithelial acini can contain motile cells. J. Cell Biol., 179, 1555-1567.
40. Beadle, C. et al. (2008) The role of myosin II in glioma invasion of the brain. Mol. Biol. Cell, 19, 3357-3368.
41. Lutz, W. et al. (1996) Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene, 13, 803-812.
42. Marson, A. et al. (2008) Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell, 134, 521-533.
43. Gualdrini, F. et al. (2010) Addiction of MYCN amplified tumours to BMYB underscores a reciprocal regulatory loop. Oncotarget, 1, 278-288.
44. Riento, K. et al. (2003) Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol., 4, 446-456.
45. Kidera, Y. et al. (2010) Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J. Exp. Clin. Cancer Res., 29, 127.
46. Liu, S. (2011) The ROCK signaling and breast cancer metastasis. Mol. Biol. Rep., 38, 1363-1366.
47. Inamdar, G.S. et al. (2010) Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem. Pharmacol., 80, 624-637.
48. Matsumura, F. (2005) Regulation of myosin II during cytokinesis in higher eukaryotes. Trends Cell Biol., 15, 371-377.
49. Li, Y. et al. (2011) Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis, 32, 1976-1983.
50. Kakisaka, T. et al. (2007) Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 852, 257-267.
51. Andersen, J.D. et al. (2010) Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J. Ovarian Res., 3, 21.
52. Kobe, B. et al. (2001) The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol., 11, 725-732.
53. Takahashi, N. et al. (1985) Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum. Proc. Natl Acad. Sci. USA, 82, 1906-1910.
54. Saito, K. et al. (2002) Gene expression profiling of mucosal addressin cell adhesion molecule-1{thorn} high endothelial venule cells (HEV) and identification of a leucine-rich HEV glycoprotein as a HEV marker. J. Immunol., 168, 1050-1059.
55. Chen, Y. et al. (2007) Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res., 67, 976-983.
56. Das, S. et al. (2010) MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res., 70, 7874-7881.
57. Tavazoie, S.F. et al. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147-152.